Financial Data and Key Metrics Changes - Net sales for Q3 2024 were $283 million, an increase of nearly 3% compared to the previous year, exceeding expectations [7] - EPS for Q3 was $1.06, up 2% year-over-year, contributing to robust free cash flow of approximately $70 million [9][21] - Year-to-date revenues reached $848.4 million, up 80 basis points, with a 1.2% growth excluding foreign exchange effects [22] Business Line Data and Key Metrics Changes - North American OTC segment revenues were flat year-over-year, with growth in Eye and Ear Care offset by declines in Women's Health and the exit from the private label business [19][23] - International OTC segment revenues increased approximately 20% year-over-year, driven by strong performance from the Hydralyte brand [20][22] Market Data and Key Metrics Changes - The e-commerce channel experienced high single-digit growth year-to-date, now representing about 15% of total sales [64] - The cough and cold category accounts for about 7% of revenue, with Q4 expected to be in line with last year's levels [39] Company Strategy and Development Direction - The company anticipates full-year revenues of $1.135 billion to $1.140 billion, with organic revenue growth of approximately 1% to 2% [32] - The long-term growth strategy aims for 2% to 3% organic growth annually, supported by strong cash flows and potential M&A opportunities [34][36] Management's Comments on Operating Environment and Future Outlook - Management noted heightened business environment uncertainty due to inflation, geopolitical events, and supply chain constraints [6] - The company remains confident in its ability to create shareholder value through cash flow generation and lower leverage [68][90] Other Important Information - The company achieved a leverage ratio of 2.9 times, aligning with its long-term objective of operating below 3 times [28][90] - Management highlighted the importance of maintaining differentiated products to compete against private labels [79] Q&A Session Summary Question: Expectations for the cough and cold category in Q4 - Management expects Q4 sales to be in line with last year's levels, as cough and cold represents about 7% of revenue [39] Question: Thoughts on Women's Health business recovery - Management anticipates recovery and stabilization for Women's Health brands, with expectations for growth next year [40] Question: Initial thoughts for FY '25 guidance - Management suggests starting with a growth expectation of 2% to 3% for top-line growth and mid-single-digit growth for the bottom line [41] Question: Flexibility to invest in the business - Management indicated increased optionality for capital deployment, including M&A and share buybacks, due to reduced leverage [47][68] Question: Performance across the portfolio - Management noted strong performance in Ear & Eye Care and International segments, while non-core brands may see declines [45] Question: Cost savings impact on gross margin - Management has begun to see benefits from cost savings, with gross margin expected to remain flat to slightly up for the year [56] Question: E-commerce performance - E-commerce grew high single digits in Q3, now accounting for about 15% of total sales [64] Question: Market share changes and competitive landscape - Management has not observed any significant share loss to private labels, emphasizing the importance of brand trust [65] Question: M&A strategy and criteria - Management maintains a consistent M&A strategy focused on leading brands with long-term growth potential [67] Question: Discussion on distribution channels - Management indicated that club channels are not a significant focus, while dollar stores have been a growing channel [73][78] Question: Impact of eye drop recalls - Management believes recalls in the eye care category may reinforce the importance of trusted brands like Clear Eyes and TheraTears [80]

leet ENSITIVE This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, leverage, free cash flow, and organic revenue growth; the Company's ability to execute on its brand-building strategy; the expected market share and consumption trends for the Company's brands; and the Company's ability to reduce debt and execute on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Ju ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q2 2024 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Phil Terpolilli - CFA Ron Lombardi - President and CEO Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Co Susan Anderson - Canaccord Genuity Jon Andersen - William Blair Keonhee Kim - Morningstar Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Prestige Consumer Healthcare Earnings Conference Call. [Operato ...

Continued Strong Results in Q2 FY 24 5 Q2 FY 24 Sales Drivers 50 PACK ORIGINAL Dual Action: Second Quarter FY 2024 Results November 2吋, 2023 I. Performance Update S E C O N D Q U A R T E R F Y 2 4 R E S U L T S eve ◼ Solid quarterly Revenue of $286.3 million, similar to prior year's record level ◼ Consumers continue to seek the benefits of trusted consumer healthcare brands ◼ Continue to benefit from leading & diversified portfolio ◼ Gross Margin as expected with sequential improvement ◼ Solid financial pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Or ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2024 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Phil Terpolilli - VP, IR and Treasury Ron Lombardi - CEO Christine Sacco - CFO Conference Call Participants Susan Anderson - Canaccord Genuity Rupesh Parikh - Oppenheimer & Co Jon Andersen - William Blair Mitchell Pinheiro - Sturdivant & Co. Operator Good day and thank you for standing by. Welcome to the Q1 2024 Prestige Consumer Healthcare, Inc. Earnings Conference Call. At this time ...

RIPLE CLEAN O Safe Harbor Disclosure F I R S T Q U A R T E R F Y 2 4 R E S U L T S I. Performance Update F I R S T Q U A R T E R F Y 2 4 R E S U L T S Business Momentum Continued in First Quarter FY 24 ◼ Continued strong performance enabled by benefits of leading & diversified portfolio 50 rac Prestige Consumer HEALTHCARE ULTIMATE All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our August 3, 2023 earnings releas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...